If Heat gets rapid approval for ImPACT plus Opdivo in NSCLC...they can then move on to get rapid approval for many other combinations with Opdivo in many other indications. In fact it could be used to gain approvals for Opdivo where Opdivo alone failed! These are multi-Billions in cancer indications. See below...
Development History and FDA Approval Process for Opdivo
Date
Article
Aug 1, 2017
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment
Feb 2, 2017
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Nov 10, 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
May 17, 2016
Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma
Jan 23, 2016
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status
Nov 23, 2015
FDA Approves Opdivo to Treat Metastatic Renal Cell Carcinoma
Oct 9, 2015
FDA Expands Approved Use of Opdivo (nivolumab) in Advanced Lung Cancer
Oct 1, 2015
BMS Receives FDA Approval for Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Melanoma
Mar 4, 2015
FDA Expands Approved use of Opdivo (nivolumab) to Treat Lung Cancer
Dec 22, 2014
FDA Approves Opdivo (nivolumab) for Advanced Melanoma
Dec 6, 2014
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
Nov 16, 2014
Study Comparing Opdivo (nivolumab) to Chemotherapy Demonstrates Survival Benefit
Oct 30, 2014
Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in NSCLC to be Presented
Oct 6, 2014
BMS Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination to Treat Non-Small Cell Lung Cancer
Sep 26, 2014
Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab)
"The refusal of the real is the number one dogma of our time" Rene Girard
